Should I buy or sell TFF Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TFF Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TFFP shares. View TFFP analyst ratings or view top-rated stocks .

What is TFF Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 1 year price objectives for TFF Pharmaceuticals' stock. Their TFFP share price targets range from $4.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,715.2% from the stock's current price. View analysts price targets for TFFP or view top-rated stocks among Wall Street analysts .

How have TFFP shares performed in 2023?

TFF Pharmaceuticals' stock was trading at $1.05 at the beginning of 2023. Since then, TFFP shares have decreased by 71.1% and is now trading at $0.3030. View the best growth stocks for 2023 here .

Are investors shorting TFF Pharmaceuticals?

TFF Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 33,100 shares, an increase of 113.5% from the October 31st total of 15,500 shares. Based on an average trading volume of 144,300 shares, the short-interest ratio is currently 0.2 days. View TFF Pharmaceuticals' Short Interest .

When is TFF Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our TFFP earnings forecast .

How were TFF Pharmaceuticals' earnings last quarter?

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) posted its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06. The firm had revenue of $0.33 million for the quarter, compared to analysts' expectations of $0.10 million. TFF Pharmaceuticals had a negative trailing twelve-month return on equity of 145.90% and a negative net margin of 2,559.40%. During the same quarter last year, the firm earned ($0.34) earnings per share.

What other stocks do shareholders of TFF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC) , VBI Vaccines (VBIV) , Akero Therapeutics (AKRO) , VYNE Therapeutics (VYNE) , Acer Therapeutics (ACER) , Aldeyra Therapeutics (ALDX) , AVEO Pharmaceuticals (AVEO) , Chiasma (CHMA) , Chimerix (CMRX) and DURECT (DRRX) .

When did TFF Pharmaceuticals IPO?

(TFFP) raised $22 million in an IPO on Friday, October 25th 2019. The company issued 4,400,000 shares at $5.00 per share. National Securities served as the underwriter for the IPO.

Who are TFF Pharmaceuticals' major shareholders?

TFF Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (4.73%), Worth Venture Partners LLC (1.15%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Aaron GL Fletcher, Carlson Capital L P, Glenn R Mattes , Harlan F Weisman, James Brian Windsor, Kirk Allen Coleman , Lung Therapeutics, Inc, Malcolm Fairbairn , Randy H Thurman, Robert S Mills, Stephen Rocamboli and Zamaneh Mikhak. View institutional ownership trends .

How do I buy shares of TFF Pharmaceuticals?

Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

TFF Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TFFP)

$0.30

0.00 (0.00%)

(As of 11/28/2023 ET)

Compare

Today's Range: $0.29
▼
$0.32
50-Day Range: $0.22
▼
$0.37
52-Week Range: $0.21
▼
$1.33

Volume: 98,140 shs
Average Volume: 161,401 shs
Market Capitalization: $16.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

TFF Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,715.2% Upside
$5.50 Price Target
Short Interest: Healthy
0.06% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.97
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.47) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

246th out of 949 stocks

Pharmaceutical Preparations Industry

103rd out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
TFF Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, TFF Pharmaceuticals has a forecasted upside of 1,715.2% from its current price of $0.30.
Amount of Analyst Coverage
TFF Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.06% of the outstanding shares of TFF Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
TFF Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TFF Pharmaceuticals has recently increased by 113.55%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
TFF Pharmaceuticals does not currently pay a dividend.
Dividend Growth
TFF Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TFFP.

3.3

News and Social Media Coverage

News Sentiment
TFF Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for TFF Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
1 people have searched for TFFP on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added TFF Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TFF Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.60% of the stock of TFF Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 17.70% of the stock of TFF Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for TFF Pharmaceuticals are expected to grow in the coming year, from ($0.47) to ($0.30) per share.
Price to Book Value per Share Ratio
TFF Pharmaceuticals has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TFF Pharmaceuticals Stock (NASDAQ:TFFP)

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.

TFFP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TFFP Stock News Headlines

November 27, 2023 | finance.yahoo.com

TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023

November 23, 2023 | morningstar.com

TFF Pharmaceuticals Inc Ordinary Shares TFFP

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 21, 2023 | msn.com

TFF Pharmaceuticals files for $100M mixed shelf

November 21, 2023 | markets.businessinsider.com

Buy Rating Reaffirmed for TFF Pharmaceuticals: Promising Clinical Trials and Sufficient Funding Forecasted

November 17, 2023 | finanznachrichten.de

TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 16, 2023 | finance.yahoo.com

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2023 Earnings Call Transcript

November 14, 2023 | finance.yahoo.com

TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 8, 2023 | finance.yahoo.com

TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing

November 7, 2023 | finance.yahoo.com

TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023

October 2, 2023 | finance.yahoo.com

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines

September 28, 2023 | finance.yahoo.com

TFF Pharmaceuticals to Participate in Upcoming Investor Conferences

August 23, 2023 | finance.yahoo.com

TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023

August 18, 2023 | benzinga.com

10% Owner At This Health Care Company Sells $94K of Stock

August 18, 2023 | finance.yahoo.com

CEO, Interim President & Vice Chairman of the Board of TFF Pharmaceuticals Picks Up 280% More Stock

August 17, 2023 | finance.yahoo.com

TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

August 17, 2023 | finance.yahoo.com

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Earnings Call Transcript

August 16, 2023 | markets.businessinsider.com

TFF Pharmaceuticals (TFFP) Receives a Buy from JonesTrading

August 16, 2023 | finance.yahoo.com

Q2 2023 TFF Pharmaceuticals Inc Earnings Call

August 15, 2023 | finanznachrichten.de

TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 15, 2023 | finance.yahoo.com

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 15, 2023 | marketwatch.com

TFF Pharmaceuticals Shares Tumble Premarket After Public Offering >TFFP

August 15, 2023 | finance.yahoo.com

TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock

August 15, 2023 | finance.yahoo.com

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 14, 2023 | finance.yahoo.com

TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock

August 9, 2023 | finance.yahoo.com

TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023

See More Headlines

Receive TFFP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TFF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/15/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TFFP
CUSIP: N/A
CIK: 1733413
Web: www.tffpharma.com
Phone: 817-438-6168
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $7.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +1,688.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,770,000.00
Net Margins: -2,559.40%
Pretax Margin: -2,559.40%
Return on Equity: -145.90%
Return on Assets: -134.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.54
Quick Ratio: 9.54

Sales & Book Value

Annual Sales: $500,000.00
Price / Sales: 34.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.66 per share
Price / Book: 0.47

Miscellaneous

Outstanding Shares: 56,090,000
Free Float: 52,948,000
Market Cap: $17.25 million
Optionable: Not Optionable
Beta: 1.20

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Harlan F. Weisman (Age 71)
President, CEO & Director
Comp: $594.48k
Mr. Kirk Allen Coleman (Age 49)
CFO, Treasurer & Secretary
Comp: $382.22k
Mr. Christopher Cano (Age 51)
COO & VP of Business Development
Comp: $353.62k
Mr. Paul F. Manley
Head of Regulatory Affairs
Dr. Zamaneh Mikhak M.D. (Age 59)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TFFP Stock Analysis - Frequently Asked Questions

Should I buy or sell TFF Pharmaceuticals stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TFF Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TFFP shares.
View TFFP analyst ratings or view top-rated stocks.
What is TFF Pharmaceuticals' stock price target for 2024?: 2 Wall Street research analysts have issued 1 year price objectives for TFF Pharmaceuticals' stock. Their TFFP share price targets range from $4.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,715.2% from the stock's current price.
View analysts price targets for TFFP or view top-rated stocks among Wall Street analysts.
How have TFFP shares performed in 2023?: TFF Pharmaceuticals' stock was trading at $1.05 at the beginning of 2023. Since then, TFFP shares have decreased by 71.1% and is now trading at $0.3030.
View the best growth stocks for 2023 here.
Are investors shorting TFF Pharmaceuticals?: TFF Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 33,100 shares, an increase of 113.5% from the October 31st total of 15,500 shares. Based on an average trading volume of 144,300 shares, the short-interest ratio is currently 0.2 days.
View TFF Pharmaceuticals' Short Interest.
When is TFF Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our TFFP earnings forecast.
How were TFF Pharmaceuticals' earnings last quarter?: TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) posted its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06. The firm had revenue of $0.33 million for the quarter, compared to analysts' expectations of $0.10 million. TFF Pharmaceuticals had a negative trailing twelve-month return on equity of 145.90% and a negative net margin of 2,559.40%. During the same quarter last year, the firm earned ($0.34) earnings per share.

What other stocks do shareholders of TFF Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), VYNE Therapeutics (VYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Chiasma (CHMA), Chimerix (CMRX) and DURECT (DRRX).
When did TFF Pharmaceuticals IPO?: (TFFP) raised $22 million in an IPO on Friday, October 25th 2019. The company issued 4,400,000 shares at $5.00 per share. National Securities served as the underwriter for the IPO.
Who are TFF Pharmaceuticals' major shareholders?: TFF Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (4.73%), Worth Venture Partners LLC (1.15%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Aaron GL Fletcher, Carlson Capital L P, Glenn R Mattes, Harlan F Weisman, James Brian Windsor, Kirk Allen Coleman, Lung Therapeutics, Inc, Malcolm Fairbairn, Randy H Thurman, Robert S Mills, Stephen Rocamboli and Zamaneh Mikhak.
View institutional ownership trends.
How do I buy shares of TFF Pharmaceuticals?: Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TFFP) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

TFF Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TFFP)

TFF Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About TFF Pharmaceuticals Stock (NASDAQ:TFFP)

TFFP Stock Price History

TFFP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TFFP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™